These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 12384827)

  • 1. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
    Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
    Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
    Ceriello A; Lush CW; Darsow T; Piconi L; Corgnali M; Nanayakkara N; Frias JP; Maggs D
    Diabetes Metab Res Rev; 2008 Feb; 24(2):103-8. PubMed ID: 17694505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.
    Riddle MC; Yuen KC; de Bruin TW; Herrmann K; Xu J; Öhman P; Kolterman OG
    Diabetes Obes Metab; 2015 Sep; 17(9):904-7. PubMed ID: 26040429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
    Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
    Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
    Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Lush CW; Chen K; Lacerte C; Burns C; McKay R; Weyer C; Horowitz M
    Obesity (Silver Spring); 2007 May; 15(5):1179-86. PubMed ID: 17495194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
    Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
    Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
    Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
    Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.